Matthew Shawn Morris - Apr 11, 2023 Form 4 Insider Report for Privia Health Group, Inc. (PRVA)

Role: Chief Executive Officer, Director
Signature: /s/ Thomas Bartrum, as attorney-in-fact
Stock symbol: PRVA
Transactions as of: Apr 11, 2023
Transactions value $: -$680,292
Form type: 4
Date filed: 4/13/2023, 04:28 PM
Previous filing: Apr 5, 2023
Next filing: May 3, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRVA	Common Stock, $0.01 par value per share	Options Exercise	$50.1K	+25.1K	+20.58%	$2.00^*	147K	Apr 11, 2023	Direct
transaction	PRVA	Common Stock, $0.01 par value per share	Sale	-$704K	-25.1K	-17.07%	$28.11	122K	Apr 11, 2023	Direct	F1, F2
transaction	PRVA	Common Stock, $0.01 par value per share	Options Exercise	$2K	+1K	+0.82%	$2.00^*	123K	Apr 12, 2023	Direct
transaction	PRVA	Common Stock, $0.01 par value per share	Sale	-$28.1K	-1K	-0.81%	$28.08	122K	Apr 12, 2023	Direct	F1, F3

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRVA	Stock Option (Right to Purchase)	Options Exercise	$0	-25.1K	-0.57%	$0.00	4.4M	Apr 11, 2023	Common Stock	25.1K	$2.00	Direct	F4
transaction	PRVA	Stock Option (Right to Purchase)	Options Exercise	$0	-1K	-0.02%	$0.00	4.4M	Apr 12, 2023	Common Stock	1K	$2.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2022.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.45 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.28 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4	All stock options are fully vested and exercisable.